Urinary retention with sertraline, haloperidol, and clonazepam combination.
Benazzi
F
F
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002998:Clonazepam / Q000008:administration & dosage / Q000009:adverse effects*; D015897:Comorbidity; D003248:Constipation / Q000139:chemically induced; D003702:Delusions / Q000175:diagnosis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D018757:GABA Modulators / Q000008:administration & dosage / Q000009:adverse effects*; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000188:drug therapy; D016584:Panic Disorder / Q000175:diagnosis / Q000188:drug therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D020280:Sertraline / Q000008:administration & dosage / Q000009:adverse effects*; D016055:Urinary Retention / Q000139:chemically induced* / Q000175:diagnosis
D014150:Antipsychotic Agents; D002998:Clonazepam; D018757:GABA Modulators; D006220:Haloperidol; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline